SESSION A: The Globalization of Drug Development

1:00pm Chairperson’s Welcome:
Leveraging Asia’s Drug Development Resources to Improve Productivity of Western Companies

• Growing and Emerging capabilities
- Chemistry and Biology services
- Animal testing 
- Bioinformatics
- Clinical development

• Drug development in Asia: challenges and opportunities
- Regulatory differences and development
- Intellectual property landscape
Eric Meyers, General Manager, Global Developer, Cambridge Healthtech Associates

1:15 Understanding Globalization Trends for Big Pharmas Move to Asia
• Understanding the macro forces 
• India vs China: Who will be the winner? 
• Build, buy or partner? What should be the strategy?
Sundeep Lal, Ph.D., M.B.A., Senior Director, Worldwide Licensing and External Research, Merck & Company

2:00 One-on-One Meetings and Refreshment Break

SESSION B: Deal Making and Partnerships

2:30 Planning Development Activities and Overcoming Logistical Challenges in Emerging Markets
Ms. Robyn Murphy, Senior Project Manager, R&D Strategic Operations, Amgen Inc.

3:15 Overcoming Challenges Unique to Partnerships between Chinese and Western Biopharmaceutical Companies
• Exploring the risks and rewards of partnering in China
• Integrating a Western management style to Eastern drug development
• Cultural challenges 
• Potential pitfalls
• Examples of successful tactics in making various aspects of a partnership in China work
Jeffrey L. Winkelhake, Ph.D., Vice President, International Operations, Sino Biopharmaceuticals Ltd. 

4:00 Afternoon Refreshment Break

4:15 Emerging Sourcing Opportunities in China: A Biopharma Perspective 
• Strategic shift in drug development - conducting activities in Asia
• Risks and benefits associated with drug development in China
• Comparative perspective with India
Alpna Seth, Ph.D., Senior Director, Global Sourcing, Biogen Idec 

5:00 Research Collaboration with Pharma and Academia in China

• Unique alliance management challenges in China • Key capabilities that must be in place to successfully manage these complex alliances • Challenges that can be overcome by partnering with a local university   - IP protection   - SFDA oversight   - GLP facilities • The opportunity for Western biopharmaceutical companies Paul L. Huang, M.D., Ph.D., Associate Professor of Medicine, Harvard Medical School, Director, Cardiac Metabolic Syndrome Program, Associate Director, Cardiovascular Research Center, Massachusetts General Hospital

5:45 Cocktail Reception

6:45 Close of Day One